Journal of Clinical Oncology
Articles in this Issue
A phase 2 study evaluating SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, + chemotherapy (chemo) in patients (pts) with first-line (1L) advanced/recurrent endometrial cancer (EC).
5627 Background: SSGJ-707 is a fully human immunoglobulin G4 bispecific antibody targeting programmed death 1 (PD-1) and v...
Uveal melanoma: A retrospective cohort study of long-term outcomes and impact of surveillance imaging intervals on metastatic burden to guide risk-adapted surveillance strategies.
e21578 Background: Uveal melanoma (UM) is associated with a high lifetime risk of metastatic disease, characterized by pro...
Perioperative cadonilimab (AK104) in locally advanced MSI-H/dMMR gastric or gastroesophageal junction adenocarcinoma and colorectal adenocarcinoma: A basket study.
4102 Background: Microsatellite instability-high (MSI-H) / deficient mismatch repair (dMMR) tumors generate abundant neoan...
A population-based modular multi-objective optimization framework with decoupled exploration and exploitation for lung adenocarcinoma histopathological subtyping in H&E whole-slide images (WSI).
e20019 Background: Current state-of-the-art artificial neural network optimizers, such as Adam, are single-objective, sing...
A phase II study of bTAE-HAIC combined with lenvatinib and camrelizumab for patients with high tumor burden hepatocellular carcinoma: The TALEM-H trial.
4123 Background: Patients with high tumor burden hepatocellular carcinoma (HCC) face a dismal prognosis. TALEM-H is a sing...
The impact of introducing cemiplimab as adjuvant treatment in high-risk cutaneous squamous cell carcinoma on NHS services and facilities.
e18031 Background: The recently published C-POST phase 3 trial has shown improved disease-free survival and reduced locore...
Real-time quantification of laryngeal motion in early glottic cancer using MR-Linac cine imaging: Implications for adaptive PTV margins.
e18109 Background: To quantify intra-fraction laryngeal motion in patients with early-stage glottic cancer treated on a 1....
SHR-1701 combined with fuzuloparib and chemotherapy as first-line therapy for advanced lung squamous cell carcinoma: Efficacy and safety results from a phase II study.
8569 Background: Although immune checkpoint inhibitors are established in the treatment of advanced lung squamous cell car...
Real-world treatment patterns and outcomes of HER2-altered NSCLC in China: A retrospective multi-center study (CHAPTER Study).
e20502 Background: The HER2-targeted therapy trastuzumab deruxtecan (T-DXd) was approved for use in China in 2024, providi...
Preeclampsia gene signatures and PD-L1 in endometrial cancer.
e22589 Background: Aggressive endometrial cancers (EC), particularly p53-abnormal (p53abn), have poor outcomes despite imm...
Epigenetic state-control and immune visibility as prognostic modules in breast cancer.
e12602 Background: Epigenetic reprogramming is proposed as an enabling dimension of cancer, but it remains unclear how exp...
Efficacy and safety of donafenib combined with hepatic artery infusion chemotherapy and sintilimab as neoadjuvant therapy for hepatocellular carcinoma: A prospective, single-arm phase II trial (Neo-DoHAICs study).
e16176 Background: Recurrence is a major cause of treatment failure in hepatocellular carcinoma (HCC), especially for tumo...
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
TPS3686 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon ca...
Phase 1b/2 trial of melphalan-percutaneous hepatic perfusion (PHP) therapy and nivolumab/relatlimab in patients with metastatic melanoma and liver metastasis.
TPS9600 Background: Despite advances with immune checkpoint inhibitors (ICIs), patients with metastatic melanoma and liver...
The SERPENTINE trial: A phase II clinical study decoding immune responses by scRNA-seq and TCR-seq analysis in patients with MSS metastatic colorectal cancer (mCRC) with and without liver metastases treated with durvalumab and tremelimumab.
3607 Background: Immune checkpoint inhibitor (ICI) therapy aims to instruct immune cells to efficiently recognize and elim...
Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: A prospective phase II clinical study.
2061 Background: High-grade gliomas exhibit extremely recurrent and resistant to treatments, and require urgent therapeuti...
ENVELOPE trial (NCCH2412): Enfortumab vedotin in patients with locally advanced or metastatic small bowel adenocarcinoma refractory or intolerant to platinum-based combination therapy—A multicenter, phase II trial (trial in progress).
TPS4269 Background: Small bowel adenocarcinoma (SBA) is a rare malignancy with limited systemic options beyond first-line...
Incidence of <i>BRCA1/BRCA2</i> mutations in ovarian cancer and other solid malignancies in Caracas, Venezuela.
e23434 Background: Ovarian cancer is the second leading cause of gynecological cancer in the United States (USA), as well...
From treatment to survivorship: The CORE randomized study of a supervised exercise intervention in early-stage breast cancer.
638 Background: Physical exercise is recommended by international guidelines to mitigate treatment-related toxicity and im...
Distant recurrence–free survival in invasive lobular carcinoma (ILC) with isolated tumor cells: Does pN0(i+) behave like node-negative or node-positive disease?
587 Background: ILC is a distinct breast cancer subtype with unique biology and clinical behavior compared with invasive d...
Safety of glucagon-like peptide-1 receptor agonists in patients receiving chimeric antigen receptor T cell or bispecific T cell engager therapy.
e24016 Background: Chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BiTE) therapies are associated...
Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line treatment for unresectable or metastatic esophageal carcinoma: A systematic review and meta-analysis of randomized trials.
e16083 Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy are standard first-line therapy for adva...
Impact of immunonutrition in patients undergoing hepatectomies for liver tumors: A randomized controlled phase II trial.
TPS4259 Background: Recent studies have demonstrated that immunonutrition has the potential to improve the host immune sta...
Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.
7514 Background: Iberdomide (Iber) is a CELMoD that binds with greater specificity & affinity to the cereblon protein...
Narcolepsy and skin cancer risk: Inverse comorbidity and the protective role of orexin deficiency.
e21575 Background: Narcolepsy is a disorder characterized by daytime sleepiness, potential cataplexy, and hallucinations....